Paul D. Rubin - 04 Dec 2025 Form 4 Insider Report for BioAge Labs, Inc. (BIOA)

Role
Chief Medical Officer
Signature
/s/ Dov A. Goldstein as attorney-in-fact
Issuer symbol
BIOA
Transactions as of
04 Dec 2025
Transactions value $
-$418,742
Form type
4
Date filed
05 Dec 2025, 18:20
Previous filing
20 Feb 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
RUBIN PAUL D Chief Medical Officer C/O BIOAGE LABS, INC., 1445A SOUTH 50TH STREET, RICHMOND /s/ Dov A. Goldstein as attorney-in-fact 2025-12-05 0001210905

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BIOA Common Stock Options Exercise $283K +68.9K $4.11 68.9K 04 Dec 2025 Direct F1
transaction BIOA Common Stock Sale -$702K -68.9K -100% $10.19 0 04 Dec 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BIOA Stock Option (Right to Buy) Options Exercise $0 -68.9K -76.02% $0.00 21.7K 04 Dec 2025 Common Stock 68.9K $4.11 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024.
F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.96 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote
F3 This option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on May 11, 2024.